论文部分内容阅读
目的探究与分析培美曲塞联合顺铂治疗晚期复发性非小细胞肺癌的临床疗效及安全性。方法选取我院收治的经手术病理、转移淋巴结活检病理、经皮肺穿刺活检、经支气管镜肺部活检均证实为非小细胞肺癌的患者60例,分为Ⅲb期和Ⅳ期。该组临床资料均采用培美曲塞联合顺铂治疗,2周后观察其疗效和不良反应情况。结果Ⅲb期患者的有效率为64.3%明显高于Ⅳ期患者的28.1%,高36.15%,P<0.05,差异具有统计学意义。不良反应主要为骨髓抑制,其中恶心为16例(26.67%),呕吐为7例(11.67%),发热为3例(5%),白细胞减少为28例(46.67%),肝功能异常为10例(16.67%)。60例患者的不良反应均较轻,对症治疗后缓解,未出现因严重不良反应而停止治疗者。结论培美曲塞联合顺铂治疗晚期复发性非小细胞肺癌不良反应较轻,疗效好,易耐受,患者满意程度高,值得推广。
Objective To investigate and analyze the clinical efficacy and safety of pemetrexed combined with cisplatin in the treatment of advanced recurrent non-small cell lung cancer. Methods Sixty patients with non-small cell lung cancer confirmed by pathology, lymph node biopsy and percutaneous lung biopsy and confirmed by bronchoscopic lung biopsy were divided into Ⅲb and Ⅳ. The clinical data of this group were treated with pemetrexed plus cisplatin, and the efficacy and adverse reactions were observed after 2 weeks. Results The effective rate of stage Ⅲb patients was 64.3%, which was significantly higher than that of stage Ⅳ patients (28.1%, 36.15%, P <0.05). The difference was statistically significant. The main adverse reactions were myelosuppression, including nausea in 16 cases (26.67%), vomiting in 7 cases (11.67%), fever in 3 cases (5%), leukopenia in 28 cases (46.67%) and liver dysfunction in 10 Cases (16.67%). Sixty patients had mild adverse reactions and were relieved after symptomatic treatment without any discontinuation of treatment due to serious adverse reactions. Conclusion Pemetrexed combined with cisplatin in the treatment of advanced recurrent non-small cell lung cancer with less adverse reactions, good curative effect, easy to tolerate, patients with high satisfaction, it is worth promoting.